Tonix Pharmaceuticals Holding Corp. — Q1 2012 Form 10-Q
Reporting period: Three months ended March 31, 2012; financial statements are unaudited. Tonix was a development-stage CNS-focused pharmaceutical company with no products for sale. It was developing reformulations of cyclobenzaprine, including TNX-102 and TNX-105, and reported no revenue.
Financial results and liquidity
| Metric | Q1 2012 | Q1 2011 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $397,628 | $79,463; up 400% |
| General and administrative expense | $762,737 | $434,215; up 76% |
| Operating loss | $1,160,365 | $513,678 |
| Interest and other financing costs, net | $901,646 expense | $22 income |
| Net loss | $2,014,988 | $513,656; up 292% |
| Basic and diluted loss per share | $0.06 | $0.03 |
| Cash used in operating activities | $1,777,614 | $380,949 |
Gross margin and profitability margins are not meaningful because the company had no revenue. At March 31, cash was $2,501,382, restricted cash was $60,199, working capital was $2,281,177, and total assets were $2,648,824. Total liabilities were $3,027,719, including a $2,714,897 warrant liability; stockholders’ deficiency was $378,895. Cash increased from $41,123 at December 31, 2011. There was no convertible-debenture balance at quarter-end, compared with $2,075,000 at year-end.
Material changes and financing
- R&D spending rose primarily with clinical work, including the TNX-102 pharmacokinetic study. G&A growth reflected higher payroll, professional fees, and public-company reporting costs. Management cited salary increases and one-time bonuses after the January financing.
- January and March financings generated aggregate cash proceeds of $4,692,765 before financing costs. The cash-flow statement reports $4,387,895 of net proceeds from the financings; operating and financing cash flows also reflect repayment of $150,000 of debentures.
- $1,925,000 of debentures was exchanged for financing units. The units included common shares and Class A and Class B warrants. A total of 7,390,292 warrants was outstanding at March 31; warrant fair-value accounting resulted in a $47,023 gain for the quarter, while the recorded warrant liability was $2,714,897.
- Financing-related noncash charges and the write-off of deferred financing costs contributed substantially to the $901,646 interest and other financing expense. The filing reports $426,152 of noncash interest associated with stock and warrants issued to debenture holders.
Outlook, risks, and other significant items
- Management expected to start the next phases of TNX-102 and TNX-105 clinical trials within 12 months, subject to raising needed funds. It expected R&D expenses to increase significantly over the next 12–24 months and anticipated continuing operating losses.
- Management believed available cash and 2012 financing proceeds would fund operating and capital requirements for approximately six months. The company had no committed additional financing, credit facility, or other external liquidity source; management said further capital would be needed and warned that failure to raise it could require substantial cost and operating reductions.
- The filing states that recurring losses, negative operating cash flow, stockholders’ deficiency, and dependence on additional funding raised substantial doubt about the company’s ability to continue as a going concern. There was no assurance of clinical success, FDA approval, or commercial viability. Trial delays, safety or efficacy issues, patient recruitment, regulatory decisions, competition, and financing availability were identified risks.
- The April 5, 2012 TNX-102 pharmacokinetic-study announcement triggered the Class B warrant measuring period; those warrants expired unexercised after the reported average share price exceeded the contract threshold. The filing text does not provide a clear value or detailed account of the study results.
- After quarter-end, the company filed amended articles increasing authorized common shares to 150 million and authorizing 5 million preferred shares. On May 9, it granted options covering 3.5 million shares, with a $1.50 exercise price. These actions may affect future dilution.
- Management concluded disclosure controls were ineffective at March 31 due to material weaknesses involving accounting staffing, segregation of duties, and technical GAAP expertise. The company hired a CFO and controller effective April 1 and engaged an outside accounting consultant; management expected to reassess remediation at June 30.
Investor facts to verify
- Current cash runway and whether additional financing was secured after management’s estimated six-month funding horizon.
- TNX-102 study findings, clinical-trial plans and progress, and the regulatory pathway and funding needs for TNX-102 and TNX-105.
- Warrant liability valuation and the potential dilution from outstanding warrants, the post-quarter option grants, and increased authorized share capacity.
- Whether the reported internal-control material weaknesses were remediated and controls subsequently tested.
- Any later developments affecting the going-concern assessment, financing commitments, or ability to continue development programs.